Literature DB >> 20619582

Access site management with vascular closure devices for percutaneous transarterial procedures.

Carlos F Bechara1, Suman Annambhotla, Peter H Lin.   

Abstract

The rising numbers in the aging population will undoubtedly lead to a corresponding increase in percutaneous endovascular procedures to address their cardiovascular health issues. With a constant drive to develop innovative treatment methods to achieve improved treatment outcomes while reducing procedural-related complications, endovascular interventionalists have focused on technologies to provide efficient hemostatic control of femoral artery access following percutaneous diagnostic or therapeutic angiographic procedures. Compared with the traditional hemostatic method using manual compression, several arterial closure devices (ACD) have been shown to reduce time of hemostasis, enable early patient ambulation, reduce hospitalization staff use, and improve patient outcome. However, these ACDs have their shortcomings as the interventionalists need to be familiar with these technologies as well as their potential complications. This article provides a comprehensive review of current closure device technologies as well as clinical experiences with these devices. The adjunctive role of these technologies in endovascular aortic aneurysm repair is also discussed.
Copyright © 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20619582     DOI: 10.1016/j.jvs.2010.04.079

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

Review 1.  Access and hemostasis: femoral and popliteal approaches and closure devices-why, what, when, and how?

Authors:  Iacopo Barbetta; Jos C van den Berg
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

2.  Angioseal™ as a hemostatic device for direct carotid puncture during endovascular procedures.

Authors:  Hugo Cuellar; Leopoldo Guimaraens; Sudheer Ambekar; Elio Vivas; Jacques Theron
Journal:  Interv Neuroradiol       Date:  2015-05-11       Impact factor: 1.610

3.  Ultrasonographic features of vascular closure devices: initial and 6-month follow-up results.

Authors:  Hye Jung Choo; Hae Woong Jeong; Jin Young Park; Sung-Chul Jin; Sung Tae Kim; Jung Hwa Seo; Sun Joo Lee; Young Mi Park
Journal:  Ultrasonography       Date:  2014-07-16

4.  24h and 30 day outcome of Perclose Proglide suture mediated vascular closure device: An Indian experience.

Authors:  Desabandhu Vinayakumar; Shajudeen Kayakkal; Sandeep Rajasekharan; Julian Johny Thottian; Prasanth Sankaran; Cicy Bastian
Journal:  Indian Heart J       Date:  2016-06-28

5.  Successful surgical retrieval of Celt ACD® vascular closure device embolised in the tibioperoneal trunk.

Authors:  Qusai Aljarrah; Ma'moon Al-Omari; Kawthar Qader; Jozef Oweis; Ahmad Althaher
Journal:  CVIR Endovasc       Date:  2018-08-07

6.  Design and Rationale of the Femoral Closure versus Radial Compression Devices Related to Percutaneous Coronary Interventions (FERARI) Study.

Authors:  Michael Behnes; Melike Ünsal; Ursula Hoffmann; Christian Fastner; Ibrahim El-Battrawy; Siegfried Lang; Kambis Mashayekhi; Ralf Lehmann; Martin Borggrefe; Ibrahim Akin
Journal:  Clin Med Insights Cardiol       Date:  2015-11-03

Review 7.  Radial artery occlusion after percutaneous coronary interventions - an underestimated issue.

Authors:  Janusz Sławin; Piotr Kubler; Andrzej Szczepański; Joanna Piątek; Michał Stępkowski; Krzysztof Reczuch
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-11-18       Impact factor: 1.426

8.  A Novel Intervention to Treat Failed Angio-Seal Footplate Deployment: Two Case Series.

Authors:  Thomas C Hall; Said Habib
Journal:  Clin Med Insights Case Rep       Date:  2019-02-08

9.  Endovascular Management of Superficial Femoral Artery Occlusion Secondary to Embolization of Celt ACD® Vascular Closure Device.

Authors:  Jehad Fataftah; Raed Tayyem; Bashar Ghosheh; Farah Tayyem; Mamoon Al-Omari
Journal:  Am J Case Rep       Date:  2020-08-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.